BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8623152)

  • 1. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Chang CT; Choc MG; Klein JB; Marsh CL; Meligeni JA; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):875-80. PubMed ID: 8623152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
    Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
    Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):968-70. PubMed ID: 8623168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.
    Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM
    Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation.
    International Neoral Renal Transplantation Study Group.
    Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group.
    Pescovitz MD; Barone G; Choc MG; Hricik DE; Hwang DS; Jin JH; Klein JB; Marsh CL; Min DI; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1997 Mar; 63(5):778-80. PubMed ID: 9075853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis.
    van der Pijl JW; Srivastava N; Denouël J; Burggraaf J; Schoemaker RC; van der Woude FJ; Cohen AF
    Transplantation; 1996 Aug; 62(4):456-62. PubMed ID: 8781610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
    Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
    Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
    Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.
    Dunn S; Cooney G; Sommerauer J; Lindsay C; McDiarmid S; Wong RL; Chang CT; Smith HT; Choc MG
    Transplantation; 1997 Jun; 63(12):1762-7. PubMed ID: 9210501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group.
    Pollak R; Wong RL; Chang CT
    Ther Drug Monit; 1999 Dec; 21(6):661-3. PubMed ID: 10604829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation.
    Roza A; Tomlanovich S; Merion R; Pollak R; Wright F; Rajagopalan P; Pruett T; Scandling J; Ryan J; Awni W; Schweitzer S; Greco R; Lam W; Nabulsi A; Hoffman R
    Transplantation; 2002 Oct; 74(7):1013-7. PubMed ID: 12394847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
    Ritschel WA
    Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients.
    Bistrup C; Nielsen FT; Jeppesen UE; Dieperink H
    Nephrol Dial Transplant; 2001 Feb; 16(2):373-7. PubMed ID: 11158415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.